共查询到20条相似文献,搜索用时 15 毫秒
1.
Ulinski T Mohan S Kiepe D Blum WF Wingen AM Mehls O Tönshoff B 《Pediatric nephrology (Berlin, Germany)》2000,14(7):589-597
Growth retardation in children with chronic renal failure (CRF) is partly due to an inhibition of insulin-like growth factor
(IGF) activity by an excess of high-affinity IGF-binding proteins (IGFBPs). The aim of this study was to analyze the serum
levels and forms of IGFBP-4 and IGFBP-5 in CRF patients using specific, recently developed radioimmunoassays (RIAs) and immunoblot
analysis. We examined 89 children [age 11.5 (2.8–19.0) years] with CRF [glomerular filtration rate 26.6 (7.0–67.4) ml/min
per 1.73 m2], nine of them with end-stage renal disease undergoing peritoneal dialysis. Serum-immunoreactive IGFBP-4 levels were fourfold
increased in CRF (prepubertal 1080±268 ng/ml; pubertal 989±299 ng/ml) compared to healthy prepubertal controls (265±73 ng/ml).
In contrast, serum IGFBP-5 levels were not significantly increased neither in prepubertal (361±120 ng/ml vs 282±75 ng/ml in
controls) nor pubertal CRF children (478±165 ng/ml vs 491±80 ng/ml in controls). Immunoblot analysis showed the presence of
intact as well as fragmented IGFBP-4 and IGFBP-5. Serum IGFBP-4, but not IGFBP-5, levels were inversely correlated with GFR
(r=–0.39, P<0.001). In prepuber- tal children, IGFBP-4 levels were inversely correlated with standardized height (r=–0.40; P<0.005). In contrast, IGFBP-5 levels were positively correlated both with standardized height (r=0.32, P<0.02) and baseline height velocity (r=0.45, P<0.005). A 3-month therapy with rhGH stimulated serum IGFBP-5 levels by 43% (P<0.01); there was no consistent effect on IGFBP-4 levels. There was a positive correlation between IGFBP-4 and IGFBP-2 (r=0.46, P<0.001); IGFBP-5 was positively correlated with IGF-I (r=0.59, P<0.001), IGF-II (r=0.42, P<0.001) and IGFBP-3 (r=0.47, P<0.001) and inversely correlated with IGFBP-1 (r=–0.41, P<0.001). In summary, serum IGFBP-4 is fourfold elevated in children with CRF in relation to the degree of renal dysfunction
and contributes to the marked increase in IGF-binding capacity in CRF serum. The inverse correlation of serum IGFBP-4 with
standardized height is consistent with its role as another inhibitor of the biological action of the IGFs on growth plate
cartilage. In contrast, serum IGFBP-5 is not elevated in CRF serum and circulates mainly as proteolysed fragments. The positive
correlation of serum IGFBP-5 with growth and its increase during GH therapy indicate that IGFBP-5 is a stimulatory IGFBP in
patients with CRF, either by enhancing IGF activity through better presentation of IGF to its receptor or by an IGF-independent
effect through activation of a specific, recently described putative IGFBP-5-receptor.
Received: 24 September 1999 / Revised: 6 January 2000 / Accepted: 13 January 2000 / Accepted: 13 January 2000 相似文献
2.
Insulin-Like Growth Factor I Is a Determinant of Hip Bone Mineral Density in Men Less Than 60 years of Age: MINOS Study 总被引:4,自引:0,他引:4
Several studies show that in elderly men bone mineral density (BMD) is not correlated with the insulin-like growth factor (IGF-I) level, but data are scanty in young men. Results of studies correlating insulin-like growth factor binding protein 3 (IGFBP-3) and BMD in men are discordant. As different hypotheses can explain the discordant results, we evaluated the correlation of BMD with serum IGF-I, IGFBP-3, and IGF-I/IGFBP-3 index in a large cohort of 721 men aged 19–85 years taking into account age, body weight, 17-estradiol, free testosterone, and parathyroid hormone. Serum IGF-I and IGFBP-3 decreased with age (r = –0.44 and r = –0.36, P = 0.0001). After adjustment for confounding variables, IGF-I correlated weakly positively with BMD and with bone mineral apparent density (BMAD) of hip as well as with cortical thickness of femoral neck, both of which are determined mainly by bone resorption, but not with bone size determined by periosteal apposition. IGF-I correlated weakly positively with BMD at the whole body and at the third lumbar vertebra IGFBP-3 and IGF-I/IGFBP-3 index did not correlate with densitometric parameters. In men aged 19–60 years, IGF-I correlated with BMD and BMAD of total hip and with cortical thickness of femoral neck positively and more strongly than in the entire cohort but not with the size of proximal femur. BMD of total hip was 6% higher in men in the highest quartile of IGF-I than in men in the lowest quartile. IGF-I, IGFBP-3, and IGF-I/IGFBP-3 index did not correlate with densitometric parameters of other sites. In the men aged more than 60 years, neither IGF-I nor IGFBP-3 nor IGF-I/IGFBP-3 index correlated with BMD, BMAD, or bone size. In men aged 19–60 years, the most significant hormonal determinants of BMD and BMAD of the hip and of the cortical thickness of femoral neck were 17-estradiol and IGF-I (P < 0.05–0.0001). In men aged more than 60 years, the most significant determinants of hip BMD were 17-estradiol and PTH. In conclusion, IGF-I seems to contribute to the inhibition of bone resorption and to maintaining bone mass of the proximal femur during the phase of slow bone loss in men aged less than 60 years. IGFBP-3 and IGF-I/IGFBP-3 index were not correlated with BMD or bone size.
Supported by a contract with INSERM/Merck Sharp & Dohme Chibret, Paris, France 相似文献
3.
Burkhard Tönshoff Werner F. Blum Otto Mehls 《Pediatric nephrology (Berlin, Germany)》1996,10(3):269-274
Serum levels of insulin-like growth factor-I (IGF-I), IGF-II, and IGF binding protein-1 (IGFBP-1), IGFBP-2, and IGFBP-3 were measured in 54 children with end-stage renal disease (ESRD). The results were compared with their respective age-dependent normal ranges. IGFs and IGFBPs were quantified by specific radioimmunoassay. Serum IGF-I in children with ESRD tended to cluster in the low-normal range. Mean age-related serum IGF-I levels were slightly, but significantly decreased (–1.08±0.17 SDS). In view of the prevailing elevated growth hormone levels in ESRD, these serum, IGF-I levels must be interpreted as inadequately low. In contrast to IGF-I, individual serum IGF-II levels were either in the uppernormal range or clearly elevated. Mean age-related IGF-II (1.09±0.15 SDS) was lightly, but significantly elevated. Mean age-related IGFBP-1 serum levels (2.20±0.10 SDS) were moderately increased, while mean age-related serum IGFBP-2 (5.65±0.36) and IGFBP-3 levels (3.60±0.19) were markedly elevated. Affinity cross-linking of125iodine-IGF-II to sera from patients with ESRD and immunoprecipitation with a specific antiserum showed that low molecular weight IGFBP-3 fragments in ESRD serum are capable of binding IGF. In patients with ESRD, a rapid and persistent decline of immunoreactive IGFBP-3 in response to restoration of renal function by renal transplantation was observed. This finding indicates that renal dysfunction contributes to high immunoreactive, IGFBP-3 levels in ESRD. In conclusion, the imbalance between normal total IGF levels and the excess of IGFBPs in ESRD is likely to play a role in growth failure in these children. 相似文献
4.
I. Kanazawa T. Yamaguchi M. Yamamoto M. Yamauchi S. Yano T. Sugimoto 《Osteoporosis international》2007,18(12):1675-1681
Summary Multivariate logistic regression analysis showed that serum IGF-I level was significantly lower in postmenopausal diabetic
women with vertebral fractures than in those without fractures. Serum IGF-I level could be clinically useful for assessing
the risk of vertebral fractures independent of BMD in postmenopausal women with type 2 diabetes.
Introduction We investigated the relationships among serum IGF-I and C-peptide levels, BMD, and vertebral fractures in postmenopausal women
with type 2 diabetes.
Methods A total of 131 postmenopausal women with type 2 diabetes were consecutively recruited, and radiographic and biochemical characteristics
were collected.
Results Either IGF-I or C-peptide was not correlated with BMD at any site or bone metabolic markers, such as osteocalcin (OC) and
urinary N-terminal cross-linked telopeptide of type-I collagen (uNTX). However, serum IGF-I level was significantly lower
in subjects with vertebral fractures than in those without fractures (mean ± SD: 106.9 ± 50.0 vs. 142.8 ± 50.8 ng/ml, p = 0.0006). When multivariate logistic regression analysis was performed with the presence of vertebral fractures as a dependent
variable and serum IGF-I adjusted for the parameters described above as independent variables, IGF-I was selected as an index
affecting the presence of vertebral fractures [odds ratio = 0.436, 95% confidential interval 0.234–0.814 per SD increase,
p = 0.0092]. This significance was almost the same after additional adjustment for lumbar BMD or C-peptide.
Conclusions Serum IGF-I level could be clinically useful for assessing the risk of vertebral fractures independent of BMD in postmenopausal
women with type 2 diabetes. 相似文献
5.
Serum insulin-like growth factor binding protein-1 levels and bone mineral density in older adults: The Rancho Bernardo Study 总被引:1,自引:0,他引:1
Simerjot K. Jassal Denise von Muhlen Elizabeth Barrett-Connor Clifford J. Rosen 《Osteoporosis international》2005,16(12):1948-1954
Insulin-like growth factor-I (IGF-I) stimulates osteoblast function, inhibits collagen matrix degradation, and is positively associated with bone mineral density in most but not all studies. We previously reported that IGF-I was positively associated with BMD at the spine and hip in women but not men. Insulin-like growth factor binding protein-1 (IGFBP-1), a potent modulator of IGF-I, is expressed in normal osteoblasts and inhibits collagen gene expression in bone, but little is known about the relationship between IGFBP-1 and bone mineral density (BMD). We report a cross-sectional study of serum IGFBP-1 levels and BMD in 1,139 community-dwelling men and postmenopausal women (not using estrogen), aged 44–98. In both sexes, IGFBP-1 levels increased linearly with age (p<0.001) and decreased with body mass index (BMI) quartile (p<0.001). After adjusting for age and BMI, there was no significant association between IGFBP-1 and BMD at the hip or spine. IGF-I and IGFBP-1 were weakly and inversely associated with each other. These findings suggest that if there is an important role for IGFBP-1 in bone metabolism, it is mediated or confounded by weight. Studies are needed to further investigate the relationship between inhibitory components of IGF-1 and bone loss. 相似文献
6.
Arundhati S. Kale Frances Liu Raymond L. Hintz Bonita K. Baker Eileen D. Brewer Phillip D. K. Lee Susan K. Durham David R. Powell 《Pediatric nephrology (Berlin, Germany)》1996,10(4):467-473
.Serum insulin-like growth factors (IGFs), which circulate bound to specific IGF binding proteins (IGFBPs), must exit the
intravascular space before acting on target tissues. Little is known about the nature of IGF/IGFBPs in extravascular fluids
of patients with chronic renal failure (CRF). Peritoneal dialysate (PD) was studied since, after a short incubation, PD contains
proteins which have entered an extravascular space; thus, IGF/IGFBP forms in PD are more likely than serum forms to interact
with target tissues. IGF-I and IGF-II, and IGFBPs 1 – 4, were readily identified by specific immunoassays and/or 125iodine-IGF ligand blotting of simultaneously obtained PD and serum samples from seven CRF children; IGFBP-3 was a major IGFBP
in PD as in serum. Where quantitated, IGF and IGFBP levels in PD were approximately 10% of serum concentrations. After separation
of PD and serum by size-exclusion chromatography, serum had more IGFBP-3 in 150-kilodalton (kDa) than 35-kDa fractions, while
PD had far less IGFBP-3 in 150-kDa than 35-kDa fractions. Immunoblot studies revealed a major 29-kDa IGFBP-3 fragment, in
addition to intact 41- and 38-kDa IGFBP-3 forms, in PD and CRF serum; the 29-kDa form predominated in the 35-kDa PD fractions.
These data suggest that the 29-kDa fragment is the IGFBP-3 form most likely to modulate IGF effects on target tissues of CRF
individuals.
Received: April 17, 1995; received in revised form September 19, 1995; accepted October 12, 1995 相似文献
7.
Gay-Hui Ho MD Chen-Yang Ji MD Beng-Hooi Phang BSc Kok-Onn Lee MD Khee-Chee Soo MD Eng-Hen Ng MD 《Annals of surgical oncology》1998,5(4):361-367
Background: Recent data suggest that tamoxifen may act by altering serum levels of insulin-like growth factors (IGFs) and their binding
proteins (BPs). This prospective paired cohort study evaluated the influence of tamoxifen on serum levels of IGFs and BPs
in postmenopausal patients with breast cancer.
Methods: Blood was collected from 32 postmenopausal patients with breast cancer before and during tamoxifen therapy for at least 6
months. All patients had undergone primary surgery. Serum concentrations of IGF-I, IGF-II, BP-1, and BP-3 were determined
by immunoradiometric assays, and Western ligand blots provided a semiquantitative measurement of BP-2, BP-3, and BP-4. Statistical
analysis was performed by paired Student'st-test.
Results: Mean serum IGF-1 level was significantly lower after tamoxifen treatment (pretreatment: 116.2 ng/mL±13.6 [SEM] vs. posttreatment:
77.5 ng/mL±7.8;P=.003). In contrast, mean IGF-II levels increased from 651.5±62.2 ng/mL to 812.5±35.1 ng/mL during treatment (P=.006). Posttreatment levels of BP-1 (92.9 ng/mL±7.5) were significantly higher compared to the pretreatment values (28.1
ng/mL±4.7;P<.001). Serum concentration of BP-3 also was elevated (pretreatment: 2228.1 ng/mL±145.2 vs. posttreatment: 3539.1 ng/mL±172.3;P<.001). Densitometric measurements showed a similar significant increase in BP-3 (P<.001) as well as BP-4 (P=.017) after hormonal therapy. Levels of BP-2 were not influenced by tamoxifen treatment.
Conclusions: These significant alterations in serum concentrations of IGFs and BPs with tamoxifen therapy suggest that the IGF system
is a potential mechanism by which tamoxifen exerts its growth inhibitory effect on breast carcinomas. 相似文献
8.
Gamze Bereket Jen Jar Lin Abdullah Bereket Charles H. Lang Frederick J. Kaskel 《Pediatric nephrology (Berlin, Germany)》1998,12(7):581-588
The kinetics of peritoneal transport of insulin-like growth factor (IGF) system-related proteins during dialysis is not well
characterized. We studied temporal changes in dialysate and serum concentrations of IGF-I and IGF-II as well as IGF binding
protein (BP)-1, -2, and -3 in ten children with end-stage renal disease (ESRD) undergoing continuous cycling peritoneal dialysis
(CCPD) during a 4-h peritoneal equilibration test (PET). Dialysate concentrations of IGF-I, IGF-II, and all three IGFBPs demonstrated
a time-dependent increase during PET. Despite their transport, the serum concentrations of these proteins did not change significantly
during the PET. Dialysate/serum ratios for IGF-I, IGF-II, and IGFBP-1, -2, and -3 were significantly increased at 2 h and
increased further at 4 h, at which time values averaged 1.3±0.2%, 3.1±0.5%, 6.2±1.0%, 2.4±0.2%, and 1.3±0.2% of serum levels,
respectively. The transperitoneal clearance (μl/min per 1.73 m2) of the three IGFBPs was inversely related to both their molecular weight and plasma concentration. However, peritoneal clearance
of IGF-I and -II was similar to that of the larger and more-abundant IGFBP-3. Mass transfer rates (μg/h per 1.73 m2) for the IGFs and their binding proteins were directly proportional to their prevailing plasma concentration. Based on estimates
of mass transfer, only a small molar excess of IGFBPs was removed from the circulation relative to the combined molar concentration
of IGF-I and IGF-II. Hence, it seems unlikely that any beneficial effect of CCPD on growth in children with ESRD is mediated
via a preferential loss of IGFBPs into the dialysate fluid.
Received August 15, 1997; received in revised form January 7, 1998; accepted January 9, 1998 相似文献
9.
The influence of serum ghrelin,IGF axis and testosterone on bone mineral density in boys at different stages of sexual maturity 总被引:1,自引:0,他引:1
Pomerants T Tillmann V Jürimäe J Jürimäe T 《Journal of bone and mineral metabolism》2007,25(3):193-197
The aim of our study was to examine the relationship between bone mineral density (BMD) and serum ghrelin, insulin-like growth
factor-1 (IGF-1), IGF-binding protein 3 (IGFBP-3), and testosterone levels in boys at different stages of puberty. The study
included 60 healthy nonobese Estonian schoolboys at the age of 10–18 years. Subjects were divided in three groups (20 boys
in each) based on the results of self-assessment using illustrated questionnaire of pubertal stage (G1, I; G2–G3, II; G3–G4,
III). Morning fasting blood samples were collected for analysis of ghrelin, testosterone, IGF-1, and IGFBP-3. Total body BMD,
lumbar BMD, lumbar apparent volumetric BMD (BMAD), and bone mineral content (BMC) were measured by DXA. Serum testosterone
concentration was the most important biochemical predictor of BMD in the total group, explaining 48.8% of variability in total
body BMD, 51.4% in lumbar BMD, and 36.8% in lumbar BMAD. Body mass and height were both related to BMD and BMC throughout
puberty. The serum IGF-1/IGFBP-3 ratio was correlated with serum testosterone (r = 0.69) and ghrelin (r = −0.58) levels, but also with total BMD (r = 0.39), lumbar BMD (r = 0.42; P < 0.001 in all cases), BMAD (r = 0.29; P < 0.01), and total BMC (r = 0.48; P < 0.001). We conclude that serum testosterone concentration and serum IGF-1/IGFBP-3 molar ratio are the major determinants
of bone mineral density in boys at different pubertal stages. Serum ghrelin concentration did not appear to have a direct
independent effect on BMD. If present, the association may be mediated through sex hormones and the GH-IGF-I axis. 相似文献
10.
I. M. Holdaway B. H. Mason A. E. Lethaby V. Singh J. E. Harman M. Maccormick I. D Civil 《ANZ journal of surgery》1999,69(7):495-500
Background : The insulin-like growth factors IGF-I and IGF-II and their major binding protein IGFBP-3 influence the growth of breast cancer cells in vitro. Some benign non-breast tumours appear to be associated with increased serum IGFBP-3 levels which would tend to reduce bioactive-free IGF concentrations. The present study investigates whether this pattern also occurs in neoplastic breast disease. Methods : Serum IGF-I, IGF-II and IGFBP-3 were measured by specific radioassay in 12 women with benign breast disease, 31 patients with breast cancer and in age-matched controls. Results : The mean (± SD) serum IGFBP-3 concentration was higher in benign breast disease (3.6 ± 0.7 mg/L) than in controls (2.7 ± 0.6 mg/L) or in breast cancer patients (2.7 ± 0.5 mg/L) (P = 0.001). Serum IGF-I and IGF-II levels were not significantly different among the groups. However, the index of free unbound IGF measured as the molar ratio of IGF-I plus IGF-II divided by IGFBP-3 was significantly lower in benign breast disease than in the other subjects. Conclusions : Either the production or clearance of IGFBP-3 is altered in benign breast disease so that there is less free IGF available to cells. This may serve to protect against malignant transformation in patients with benign breast disorders. 相似文献
11.
Robert G. Bing-You Marie-Claire Denis Clifford J. Rosen 《Calcified tissue international》1993,52(3):183-187
Summary The adverse consequences of growth hormone (GH) deficiency (GHD) on bone growth in children is well described. Whether adult GHD is associated with bone loss is unknown. We evaluated 14 patients with hypothalamicpituitary tumors (HPT) acquired during adulthood (5 men, 9 women;
age=48.1±4.6 years;
BMI=28.8±1.7) and 14 age-, sex-, and weight-matched controls. Nine HPT patients were receiving gonadal steroid replacement therapy for a mean of 11 years. All subjects had basal IGF-I and IGFBP-3 levels prior to testing with GH-releasing hormone [1 g/kg IV bolus; responses expressed as maximum percentage increase above baseline (PERGH)]. Bone mineral density (BMD) of the spine, hip, and total body were measured by dual-energy X-ray absorptiometry. Mean BMD Z-scores of the HPT patients were significantly lower in the femoral neck, Ward's triangle, and trochanter than in controls (all P<0.05). Mean total body BMD (g/cm2) was also lower in the patient group (1.04±0.03 versus 1.13±0.03, P<0.05). For the subgroup of HPT patients receiving conventional gonadal steroids, mean BMD Z-scores of the lumbar spine also were significantly lower than controls (-1.84±0.43 versus -0.57±0.46, P<0.05). PERGH and IGF-l were correlated with Z-scores of the femoral neck (r=0.47, P<0.01; r=0.45, P<0.01) and Ward's triangle (r=0.47, P<0.01; r=0.41, P<0.05). These results indicate that adults with previous HPTs have significantly lower spine and hip BMD compared with healthy controls, regardless of gonadal steroid therapy, and that this premature bone loss is associated with relative GHD. IGF-I and PERGH measurements might be useful markers to identify such patients at risk for reduced BMD. 相似文献
12.
Ippei Kanazawa Toru Yamaguchi Masahiro Yamamoto Mika Yamauchi Shozo Yano Toshitsugu Sugimoto 《Calcified tissue international》2009,85(3):228-234
We examined whether or not BMD or bone markers were useful for assessing the risk of vertebral fractures in 248 Japanese men
with type 2 diabetes. We analyzed the relationships between bone markers (osteocalcin [OC], bone-specific alkaline phosphatase
[BAP], urinary N-terminal cross-linked telopeptide of type-I collagen) or BMD and HbA1c, urinary C-peptide, insulin-like growth factor-I (IGF-I), parathyroid hormone, 1,25(OH)2 vitamin D, and the presence of prevalent vertebral fractures. Multiple regression analysis adjusted for age, body height,
weight, duration of diabetes, and serum creatinine showed that serum OC and OC/BAP ratio were correlated negatively with HbA1c (P < 0.01) and positively with IGF-I (P < 0.01). Multivariate logistic regression analysis adjusted for the above parameters showed that serum OC/BAP ratio was inversely
associated with the presence of vertebral fractures (odds ratio = 0.695, P < 0.05). This association was still significant after additional adjustment for lumbar or femoral neck BMD. Our results suggest
that poor diabetic control and lower IGF-I level are linked to impaired bone formation and resultant reduction in OC/BAP ratio
in men with type 2 diabetes. The OC/BAP ratio could be clinically useful for assessing the risk of vertebral fractures independent
of BMD in diabetic men. 相似文献
13.
Growth hormone/insulin-like growth factor system in children with chronic renal failure 总被引:4,自引:3,他引:1
Disturbances of the somatotropic hormone axis play an important pathogenic role in growth retardation and catabolism in children with chronic renal failure (CRF). The apparent discrepancy between normal or elevated growth hormone (GH) levels and diminished longitudinal growth in CRF has led to the concept of GH insensitivity, which is caused by multiple alterations in the distal components of the somatotropic hormone axis. Serum levels of IGF-I and IGF-II are normal in preterminal CRF, while in end-stage renal disease (ESRD) IGF-I levels are slightly decreased and IGF-II levels slightly increased. In view of the prevailing elevated GH levels in ESRD, these serum IGF-I levels appear inadequately low. Indeed, there is both clinical and experimental evidence for decreased hepatic production of IGF-I in CRF. This hepatic insensitivity to the action of GH may be partly the consequence of reduced GH receptor expression in liver tissue and partly a consequence of disturbed GH receptor signaling. The actions and metabolism of IGFs are modulated by specific high-affinity IGFBPs. CRF serum has an IGF-binding capacity that is increased by seven- to tenfold, leading to decreased IGF bioactivity of CRF serum despite normal total IGF levels. Serum levels of intact IGFBP-1, -2, -4, -6 and low molecular weight fragments of IGFBP-3 are elevated in CRF serum in relation to the degree of renal dysfunction, whereas serum levels of intact IGFBP-3 are normal. Levels of immunoreactive IGFBP-5 are not altered in CRF serum, but the majority of IGFBP-5 is fragmented. Decreased renal filtration and increased hepatic production of IGFBP-1 and -2 both contribute to high levels of serum IGFBP. Experimental and clinical evidence suggests that these excessive high-affinity IGFBPs in CRF serum inhibit IGF action in growth plate chondrocytes by competition with the type 1 IGF receptor for IGF binding. These data indicate that growth failure in CRF is mainly due to functional IGF deficiency. Combined therapy with rhGH and rhIGF-I is therefore a logical approach.This work was presented in part at the IPNA Seventh Symposium on Growth and Development in Children with Chronic Kidney Disease: The Molecular Basis of Skeletal Growth, 1–3 April 2004, Heidelberg, Germany 相似文献
14.
E. Vega G. Ghiringhelli C. Mautalen G. Rey Valzacchi H. Scaglia C. Zylberstein 《Calcified tissue international》1998,62(5):465-469
The bone mineral density (BMD) at the lumbar spine, proximal femur, and total skeleton was evaluated in 38 men with primary
osteoporosis and vertebral fractures. BMD of the patients was significantly reduced over all skeletal areas compared with
controls. The Z-score of the lumbar spine (−2.8 ± 0.9) was less than that of the other areas (P < 0.001) except the legs (−2.5 ± 1.1) (p.n.s.) showing that bone loss had a tendency to be greater over the axial skeleton.
Vertebral dimensions compared with age-matched controls were as follows: projected L2–L4 area (cm 2): 45.7 ± 5.6 versus 53.7
± 3.6 (P < 0.001); vertebral width (cm): 4.37 ± 0.44 versus 4.90 ± 0.36 (P < 0.001). Serum biochemical parameters and testosterone levels were similar between osteoporotic and control men. We conclude
that men with vertebral osteoporotic fractures have reduced vertebral BMD and vertebral dimensions compared with age-matched
controls. Thus, these findings indicate that the achievement of a reduced bone size at the end of the growth period or a failure
of periosteal increase during adult life is likely to contribute to the pathogenesis of the vertebral fractures observed in
older men.
Received: 31 January 1997 / Accepted: 2 July 1997 相似文献
15.
Daniela Kiepe Eva-Maria Rüth Werner F. Blum Subburaman Mohan Lutz T. Weber Burkhard Tönshoff 《Pediatric nephrology (Berlin, Germany)》2010,25(4):659-667
The post-transplant bone disease of the peripheral skeleton in pediatric renal transplant recipients is characterized by an
inadequately thin bone cortex in relation to muscular force. A major hormonal modulator of periosteal growth is the insulin-like
growth factor (IGF)/IGF binding protein (IGFBP) system. We therefore hypothesized that the reduced cortical thickness in these
patients may be due to functional IGF deficiency. To test this hypothesis, we investigated 55 patients (mean estimated glomerular
filtration rate 86.3 ± 30.0 ml/min/1.73 m2) in a cross-sectional study. Parameters of macroscopic bone architecture and forearm muscle size were analyzed by peripheral
quantitative computed tomography (pQCT), and serum IGF/IGFBP system components were measured by specific radioimmunoassays.
The mean (± standard deviation) standardized serum IGF-I (0.20 ± 1.16 score) level was normal, while the mean IGF-II (1.16 ± 0.11
score) level was significantly elevated. Serum IGFBP-1 and IGFBP-2 levels were not altered, whereas the IGFBP-3 (1.34 ± 0.15
score) level was significantly increased. The serum IGFBP-4 level was slightly elevated (by 11%), the IGFBP-6 level was markedly
(2.3-fold) elevated, while the IGFBP-5 level was comparable to that of the control. The respective age-adjusted cortical thickness
at both the proximal (r = 0.407, P < 0.005) and distal (r = 0.383, P < 0.01) forearm was positively correlated with the standardized serum IGF-I level. In conclusion, the serum IGF/IGFBP system
in pediatric renal transplant recipients is characterized by an increase in the levels of the inhibitory IGFBPs, IGFBP-3,
-4 and -6, resulting in a functional IGF deficiency. The positive correlation of IGF-I with cortical thickness underlines
the importance of this hormonal system in the modeling of bone, particularly periosteal growth. 相似文献
16.
Dae-Yeol Lee Pinchas Cohen Alan M. Krensky Ron G. Rosenfeld Peter D. Yorgin 《Pediatric nephrology (Berlin, Germany)》1993,7(4):416-423
The insulin-like growth factors, IGF-1 and IGF-II, are polypeptides that potentiate cellular growth. In addition to binding to specific cell surface receptors, the IGFs bind with high affinity to a family of proteins, the insulin-like growth factor binding proteins (IGFBPs). Serum and urine IGFBP patterns are altered in individuals with chronic renal failure (CRF). We recently reported that the urinary IGFBP pattern of CRF patients is unique for increased insulin-like growth factor binding protein-1 (U-IGFBP-1) levels. In this study, we used western ligand blotting (WLB), western immunoblotting (WIB), and radioimmunoassay (RIA) to further evaluate serum and urine IGFBP profiles of children with CRF (n=14). Five patients with CRF displayed decreased serum IGFBP-3 profiles by WLB. Serum IGFBP-3 WIB profiles were remarkable for 30- and 20-kDa fragments of IGFBP-3 not seen in control serum. Serum IGFBP-3 levels, as determined by RIA, were slightly elevated. Serum levels of IGFBP-2 also were increased, although not at a level reaching statistical significance. WLB of CRF urine revealed a large increase in U-IGFBP-1 and a complete absence of urinary IGFBP-3. Recent studies of serum from pregnant women and seminal plasma have demonstrated a similar absence of intact IGFBP-3, due to the presence of a specific IGFBP-3 protease. To evaluate whether an IGFBP-3 protease accounts for the absence of intact U-IGFBP-3 in children with CRF, urine and serum samples from individuals with CRF and controls were tested. An IGFBP-3 protease assay using concentrated urine revealed the presence of two distinct proteases found only in the CRF urines. Serum IGFBP-3 protease activity was no greater in patients with CRF than in controls. We conclude that the decrease in intact urinary IGFBP-3 is due to proteolysis by an IGFBP-3 protease. 相似文献
17.
Margaret J. van Renen Sabine Harrer Ken F. Jureidini Anne A. Martin 《Pediatric nephrology (Berlin, Germany)》1996,10(4):483-487
A
bstract. Three short children with severe chronic renal failure were treated with recombinant human growth hormone (rhGH) for 2 years.
Each received a transplant in the 2nd year. Serum collected before and during rhGH therapy was analysed retrospectively by
Western ligand blot and immunoblotting techniques. In addition, radioimmunoassays for insulin-like growth factor-I (IGF-I),
IGF binding protein-3 (IGFBP-3), acid-labile subunit (ALS) and IGFBP-1 were performed. IGFBPs in serum, detected by Western
ligand blot, were identified as IGFBP-3, -2, -1 and -4 by immunoblot. The serum concentration of IGF-I in each child rose
approximately fourfold with rhGH before transplantation and subsequently remained elevated. IGFBP-3 levels rose to double
the pretreatment value, but dropped to normal levels following transplantation, while ALS rose with rhGH treatment and remained
increased after transplantation. IGFBP-1 levels changed little with rhGH but fell following transplantation. A low molecular
weight form of IGFBP-3 was noted at 30 kilodaltons on immunoblot which was not clearly seen on the ligand blot. IGFBP-2 was
present as a distinct band on Western ligand blot before transplantation and appeared decreased in intensity subsequently.
IGFBP-1, seen on immunoblot clearly before transplant, disappeared after the transplant. rhGH successfully improved growth
in these children, in association with a fourfold increase in IGF-I levels, which was maintained following transplantation.
The reduction in IGFBPs following transplantation suggests correction of impaired clearance by the diseased kidney.
Received September 5, 1994; received in revised form November 8, 1995; accepted November 21, 1995 相似文献
18.
E. Romagnoli S. Minisola MD V. Carnevale R. Rosso M. T. Pacitti A. Scarda L. Scarnecchia G. Mazzuoli 《Osteoporosis international》1994,4(6):305-308
The study investigated possible menopause-related changes in circulating insulin-like growth factor binding protein 3 (IGFBP-3) levels and their relationship with insulin-like growth factor I (IGF-I) plasma levels. Forty-three healthy women, aged 45–55 years, were studied (22 premenopausal and 21 postmeno-pausal, matched for age and body mass index); in all subjects plasma IGF-I and IGFBP-3 levels were measured by radioimmunoassay. No difference was found between mean IGFBP-3 plasma levels in the two groups studied (premenopausal 3.42±0.49 v postmenopausal 3.46±0.58 mg/l), while mean IGF-I levels were significantly lower in postmenopausal as compared with premenopausal women (136.7±37.86 v 175.7±51.91 ng/ml,p<0.02). Multiple regression analysis showed no significant effect of age, body mass index and years since menopause on IGFBP-3 levels; however, considering the IGF-I/IGFBP-3 ratio as a possible parameter of circulating free somatomedin C, an inverse correlation was found with years since menopause (n=43,r=–0.499,p<0.001). We conclude that lack of oestrogen induces different effects on circulating IGF-I and IGFBP-3, possibly reflecting a real decrease in IGF-I activity. 相似文献
19.
Circulating Insulin-Like Growth Factor System Changes in Women with Acute Estrogen Deficiency Induced by GnRH Agonist 总被引:1,自引:0,他引:1
S. Poiraudeau C. Roux F. De Ceuninck L. Tsagris D. Borderie B. Cherruau M.-F. Dumontier M. Corvol 《Osteoporosis international》1997,7(5):463-470
This prospective longitudinal study was undertaken to examine the short-term effects (6 months) of estrogen withdrawal on
the circulating IGF system. A series of 40 patients suffering from endometriosis was studied before and after a 6-month treatment
period with gonadotrophin releasing hormone (GnRH) agonist and calcium, with or without nasal salmon calcitonin. The plasma
concentrations of insulin-like growth factor I (IGF-I9 and insulin-like growth factor II (IGF-II) were measured by radioimmunoassay
and radioreceptor assay respectively. Plasma IGF binding proteins (IGFBPs) were quantified and characterized by ligand blot
and immunoblot. In all patients, a secondary hypoestrogenism was observed, including a 4% decrease in lumbar bone mineral
density (L-BMD). The plasma IGF-I and IGF-II concentrations increased after treatment (24%, p < 0.0005 and 40%, p < 0.004 respectively), with no significant difference between the treatment groups. There was a positive correlation between
plasma IGF-I (but not IGF-II) changes and changes in urinary deoxypyridinoline (r = 0.32, p < 0.05), urinary C telopeptide of type I collagen (r = 0.33, p < 0.04) and total plasma alkaline phosphatases (r = 0.33, p < 0.04). No correlation was found between IGF-I and L-BMD changes, while there was a positive correlation between the changes
in plasma IGF-II and L-BMD (r = 0.32, p < 0.05). Ligand blot analysis revealed a significant increase in IGF-II binding to a 29–31 kilodalton region where positive
staining with specific antibodies to IGFBP-3 or IGFBP-1 was observed. In conclusion, IGF-I and IGF-II plasma concentrations
are both increased following a short period of treatment with a GnRH agonist. The changes in individual IGF peptides are differently
correlated with changes in markers of bone remodelling and L-BMD. 相似文献
20.
H.-Y. Zhao J.-M. Liu G. Ning Y.-J. Zhao Y. Chen L.-H. Sun L.-Z. Zhang M.-Y. Xu J.-L. Chen 《Osteoporosis international》2008,19(2):221-226
Summary Serum IGF-I level was negatively correlated with OPG and OPG/RANKL ratio, but positively correlated with RANKL. Serum OPG
level in the highest quintile of IGF-I was significantly lower than that in the lowest. We conclude that the effect of IGF-I
on bone remodeling may be mediated by the OPG/RANKL system.
Introduction Insulin-like growth factor I (IGF-I) is an important factor in coupling bone remodeling, activating both formation and resorption.
Compared with the many studies on the role of IGF-I in bone formation, the information regarding its effects on bone resorption
is limited and conflicting. The balance of the two peptides produced by osteoblasts, osteoprotegerin (OPG) and receptor activator
of nuclear factor-κB ligand (RANKL), is critical for the bone resorption process. Our study was designed to analyze the relationships
of serum concentrations of IGF-I with OPG, RANKL, OPG/RANKL ratio as well as BMDs in healthy Chinese women.
Methods BMDs at lumbar spine and proximal femur in 504 pre- and postmenopausal women were measured by DXA. Serum levels of IGF-I,
OPG and RANKL were also measured. Pearson’s correlation and partial correlation analysis, ANOVA, covariance analysis and stepwise
multiple regression analysis were used as appropriate.
Results Age was negatively correlated with serum levels of IGF-I (r = −0.702, p < 0.001). IGF-I was negatively correlated with OPG and OPG/RANKL ratio, but positively correlated with RANKL. The relationship
between IGF-I and BMDs disappeared after adjustment for age. In postmenopausal women, IGF-I was lower in women with osteoporosis
than in those with normal BMD (p = 0.056), but no differences were found among OPG, RANKL and OPG/RANKL ratio. Serum levels of OPG in the highest quintile
of IGF-I were significantly lower than those in the lowest quintile of IGF-I, while no difference was found in RANKL. In the
multiple regression analysis model, serum levels of IGF-I were the main determinants of the bone mass in Chinese women.
Conclusions In conclusion, the relationship between decreasing IGF-I and BMDs in healthy Chinese women influenced by age, whereas the
effect of IGF-I on bone remodeling (bone resorption) may be mediated by the OPG/RANKL system. 相似文献